Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 1.00 |
| ▸ | C1R | P00736 | 4/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.53 |
| ▸ | F7 | P08709 | 2/20 | 0.53 |
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849973 | 1.00 | ELANE (1.00) | ELANEC1RAPEX1PBRM1F10 | |
| SCHEMBL9984780 | 0.88 | ELANE (1.00) | ELANEC1RPBRM1MAPTMEN1 | |
| SCHEMBL17554052 | 0.88 | ELANE (0.79) | ELANEC1RAPEX1F10F7 | |
| SCHEMBL913466 | 0.86 | ELANE (0.75) | ELANEC1RAPEX1PBRM1F7 | |
| SCHEMBL29574035 | 0.83 | ELANE (1.00) | ELANEC1RPBRM1MAPTMEN1 | |
| SCHEMBL9985824 | 0.83 | ELANE (1.00) | ELANEC1RPBRM1MAPTMEN1 | |
| SCHEMBL9984683 | 0.83 | ELANE (1.00) | ELANEC1RPBRM1KDM4EALDH1A1 | |
| SCHEMBL4190607 | 0.83 | ELANE (0.79) | ELANEC1RPBRM1F2MAPT | |
| SCHEMBL913425 | 0.82 | ELANE (0.69) | ELANEC1RAPEX1F10F7 | |
| SCHEMBL10507270 | 0.82 | ELANE (0.71) | ELANEC1RPBRM1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHANG GUNG UNIVERSITY (TW) | 2011-12-29 | — | — | US | claimed |
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-01-20 | — | — | US | disclosed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| EP-3027594-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014972-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2015-02-05 | — | — | WO | disclosed |
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHANG GUNG UNIVERSITY (TW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | ELANE 3447/4885C1R 2738/4885APEX1 3859/4885 |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | ELANE 3447/4885C1R 2738/4885APEX1 3859/4885 |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | ELANE 3534/4885C1R 2739/4885APEX1 3862/4885 |
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CYP4X1, CYP2B6, CYP2C19 | ELANE 3461/4885C1R 84/4885APEX1 3474/4885 |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | ELANE 3534/4885C1R 2739/4885APEX1 3862/4885 |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | ELANE 3534/4885C1R 2739/4885APEX1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.